Pharmaceuticals - Community Register


List of refusals for human medicinal products


Product name: Acrescent
Active substance: memantine hydrochloride / donepezil hydrochloride
Indication: Treatment of patients with moderate to moderately severe Alzheimer’s disease who are already on a stable daily dose of 20 mg memantine and 10 mg donepezil.
Marketing Authorisation Holder: H. Lundbeck A/S

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/02/2013 Centralised - Refusal of marketing authorisation EMEA/H/C/2424 (2013)1099 of 20/02/2013
02/04/2013 Corrigendum (2013)1969 of 27/03/2013